Increased miR-320 impairs lipid metabolism and gluconeogenesis by targeting adiponectin receptor 1 (AdipoR1), and thus miR-320 may be taken as a possible target for T2D therapy [40]. Here, ADIPOR1 is linked to type 2 diabetes mellitus.